FERRING-PHARMACEUTICALS
9.4.2024 07:16:34 CEST | Business Wire | Press release
Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.
The year marked a major turning-point for Ferring with the launch of two innovative first-in-class medicines in the United States. Rebyota® (fecal microbiota, live – jslm) is the first microbiome-based live therapeutic ever approved by the US Food and Drug Administration, while Adstiladrin® (nadofaragene firadenovec-vncg) represents a new form of gene therapy with the potential to transform the treatment of certain urological cancers. The commercial potential of Adstiladrin was recognised by a US$500 million royalty financing agreement with Royalty Pharma, a leading funder of innovation in the biopharmaceutical sector.
Ferring is evolving to make the most of these opportunities, and there were a number of significant changes to the senior leadership. In July 2023, Jean-Frédéric Paulsen became Chairman of the company founded by his grandfather Dr. Frederik Paulsen and Eva Paulsen in 1950. Lars Rebien Sørensen, who has held the post of Chairman since 2021, remains on the Board as Vice-Chairman, ensuring continuity of leadership. Jeffrey Hobbs stood down as Vice Chairman and Executive Director following several decades of outstanding contribution to the Ferring Group. Hélène Ploix and Alexandra, Countess of Frederiksborg, also stood down from the Board of Directors after many years of invaluable service.
Two new members joined the Board of Directors – Viviane Monges, who took over as Chair of the Audit and Finance Committee, and Henrik Normann, member of the Board of Directors, who was previously President and CEO of Nordic Investment Bank. In April 2024, Per Falk stood down as President, a position he held since 2019. Ferring’s Executive Committee was strengthened by the appointment in January 2023 of Pierre-Yves Berclaz as Chief Medical Officer, and in January 2024 Cyril Grandchamp-Desraux as Chief Commercial Officer.
Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “The launch of two groundbreaking medicines in the US, along with the other important changes in 2023, mark the start of an exciting new phase of growth for Ferring. As we look forward to another year filled with enormous potential, I am confident in the qualities of our senior executive team and the thousands of colleagues worldwide whose dedication and expertise will help to ensure that we succeed in our mission of building families and helping people live better lives.”
Ferring has also maintained its environmental, social and governance (ESG) progress and, in 2023, embarked on a programme to embed sustainability into its activities worldwide. In a major milestone, we marked the tenth anniversary of #ProjectFamily Safe Birth, a public-private partnership which aims to address postpartum haemorrhage (PPH), the leading cause of maternal mortality worldwide.1 In 2023, we provided one million doses of Carbetocin Ferring, our heat-stable medicine for the prevention of PPH, at a not-for-profit, affordable price to public and not-for-profit health facilities in low and lower-middle income countries. Ferring’s contribution was recognised with inclusion in Fortune’s ‘Change the World’ List of companies that have had the greatest impact in addressing society’s unmet needs.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).
______________________________
1 World Health Organization. A Roadmap to Combat Postpartum Haemorrhage between 2023 and 2030. 2023. Available at https://cdn.who.int/media/docs/default-source/reproductive-health/maternal-health/pph-roadmap.pdf?sfvrsn=db36b511_3 Accessed April 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408912190/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Money20/20 Europe Celebrates Ten Years of Industry Leadership as AI, Digital Assets and Financial Sovereignty Take Centre Stage8.6.2026 17:37:00 CEST | Press release
Money20/20, the world's leading fintech show and the place where money does business, celebrated a major milestone with its 10th Europe edition, convening more than 7,500 attendees, one in three at C-suite level, and over 2,300 companies from over 105 countries in Amsterdam, for three days of industry-defining announcements, strategic partnerships, and dealmaking that set the agenda for the future of financial services. Featuring more than 450 speakers across six stages, Money20/20 Europe welcomed leaders from banking, fintech, payments, policy, technology and digital assets to explore the forces reshaping the future of money. “This year’s show demonstrated that financial services have entered a new phase of transformation,” said Bryony Naylor, Vice President of Money20/20 Europe. “Across the show floor and on stage, we saw leaders move beyond discussing what’s next to actively building it. From AI and digital identity to financial sovereignty and digital assets, the conversations and
Liberty Latin America Selects BTS as Exclusive A2P Messaging Managed Services Partner Across All Its Markets8.6.2026 17:36:00 CEST | Press release
BTS announced today that it has been chosen as the exclusive provider of managed A2P SMS services for Liberty Latin America (LLA), supporting the company’s efforts to strengthen revenue protection, fraud mitigation, traffic intelligence, and operational visibility across its markets. The agreement reinforces LLA’s A2P messaging strategy throughout a broad regional footprint and establishes a coordinated operating model to improve control, visibility, and monetization of A2P traffic across its markets. The partnership will support revenue maximization, stronger fraud protection and grey-route mitigation, enhanced real-time traffic visibility, operational reporting and analytics, revenue assurance, and 24x7x365 managed services support. The agreement spans 25 markets and reflects a high level of operational trust in BTS’ ability to deliver consistent performance across diverse regulatory, technical, and commercial environments. “This agreement gives us a stronger and more consistent oper
The Estée Lauder Companies Strengthens UK Manufacturing Network as Whitman Facility Celebrates 60 Years of British Craftsmanship8.6.2026 17:14:00 CEST | Press release
As The Estée Lauder Companies’ (NYSE: EL) Whitman manufacturing facility celebrates its 60th anniversary, the company today announced a strategic investment that will strengthen its UK manufacturing network, further reinforcing its long-standing commitment to British craftsmanship, innovation, and growth in prestige fragrance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608415843/en/ From left to right: Jo Dancey, Global Brand President, Jo Malone London; Alex Gregorian, SVP, Global Manufacturing & Engineering; Roberto Canevari, Chief Value Chain Officer; Nadine Graf, President, EUKEM; Stéphane de La Faverie, President and Chief Executive Officer; William P. Lauder, Chair of the Board of Directors; Maria Genouzos, VP, EUKEM and APAC Manufacturing; Pernilla Nyberg, SVP, General Manager, UK & Ireland; Jamal Chamariq, SVP, EUKEM & TR Value Chain; and Ben Smith, Whitman Plant Manager, celebrate the 60th anniversary of The
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination8.6.2026 16:16:00 CEST | Press release
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today that the registration statement on Form F-4 (the “Registration Statement”), relating to their previously announced business combination, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608520188/en/ IQM Radiance quantum computer The extraordinary general meeting of RAAQ’s shareholders in connection with the proposed business combination (the “Extraordinary General Meeting”) will be held on June 25, 2026. The proxy statement/prospectus relating to the Extraordinary General Meeting was mailed to RAAQ’s shareholders of record
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Monster Hunter: World, released in 2018, surpassed 30 million units as Capcom looks to expand its global user base – Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Furthe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom